Chinese officials have said that COVID-19 vaccine will be ready for the public by November

There are currently nine vaccine candidates in late-stage human trials, although pharma giant AstraZeneca paused their trials after a volunteer developed an unexplained illness.

Agence France-Presse September 16, 2020 16:16:13 IST
Chinese officials have said that COVID-19 vaccine will be ready for the public by November

Chinese pharma companies Sinovac Biotech and Sinopharm even putting their vaccine candidates on display at a trade fair in Beijing this month.

A China-developed coronavirus vaccine could be ready for the public as early as November, a Chinese official has told state television, as the global race to clear the final round of trials heats up.

Chinese manufacturers have been bullish about development, with companies Sinovac Biotech and Sinopharm even putting their vaccine candidates on display at a trade fair in Beijing this month.

Representatives of the firms told AFP that they hope their vaccines will be approved after phase 3 trials as early as year-end.

And on late Monday, the chief biosafety expert at the Chinese Centre for Disease Control told state broadcaster CCTV that a vaccine would be available to the general public "around November or December."

Wu Guizhen did not specify which vaccine she was referring to but said,"based on phase 3 clinical results, the current progress is very smooth."

Wu added that she had taken a vaccine in April and has felt good over the past few months, although she did not specify which candidate she had taken.

There are currently nine vaccine candidates in late-stage human trials, although some have hit recent obstacles -- pharma giant AstraZeneca and Oxford University momentarily paused clinical trials last week after a volunteer developed an unexplained illness.

Some of China's vaccine candidates have already been offered to essential workers under an emergency use programme.

A Sinovac spokesman told AFP this month that "tens of thousands" of people had voluntarily taken its vaccine, including 90 percent of its employees and their families -- between 2,000 and 3,000 people.

In June, China's military approved a vaccine for use within its ranks developed by its research unit and a biotech firm.

Updated Date:

also read

Serum Institute of India to resume trial for Oxford's COVID-19 vaccine candidate after DCGI nod
India

Serum Institute of India to resume trial for Oxford's COVID-19 vaccine candidate after DCGI nod

The trials were halted after AstraZeneca, the pharma company responsible for the vaccine, paused its UK trials after one of the volunteers developed a 'serious ailment'

Coronavirus Updates: Ahead of West Bengal Assembly's Monsoon session, eight, including two staff and four cops, test positive
India

Coronavirus Updates: Ahead of West Bengal Assembly's Monsoon session, eight, including two staff and four cops, test positive

Coronavirus Updates: A total of 467 persons were tested at a temporary testing centre on Tuesday. The House will be in session only on 9 September as opposed to the two days proposed earlier

RDIF, Dr Reddy's Lab tie up for Sputnik V human trials, distribution of 100 mn doses of the COVID-19 vaccine in India
India

RDIF, Dr Reddy's Lab tie up for Sputnik V human trials, distribution of 100 mn doses of the COVID-19 vaccine in India

As of 1 August, Phase I and II of the vaccine were complete and by 11 August, Russian President Vladimir Putin had registered it as the world's first vaccine.